UPLIZNA® (inebilizumab-cdon) is a twice-yearly treatment for neuromyelitis optica spectrum disorder (NMOSD) proven to help reduce relapses that may lead to permanent disability. The treatment is administered with 90-minute intravenous (IV) infusions twice a year (after two initial start-up doses).
Note: Please speak with your healthcare provider for more information if you think this therapy might be right for you.
How do I make a referral or transition my treatment to Infusion Associates?
3. One of our intake specialists will contact your healthcare provider to confirm receipt of your referral.
4. We will then verify benefits, obtain any required prior authorizations, and contact you to schedule an appointment.